GG00BMFG5F62 - Common Stock
OKYO PHARMA LTD
NASDAQ:OKYO (9/16/2024, 8:00:02 PM)
After market: 1.04 0 (-0.48%)1.045
+0.01 (+1.46%)
OKYO Pharma Ltd. operates as a biopharmaceutical company, which engages in the development of therapeutics for inflammatory eye diseases and chronic pain. The firm is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The firm is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The firm also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. The company is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
OKYO PHARMA LTD
Floor 4, 14/15 Conduit St
London
P: 442074952379
Employees: 7
Website: https://okyopharma.com/
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
In today's session, these stocks are experiencing unusual volume.
LONDON and NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing...
Here you can normally see the latest stock twits on OKYO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: